Maternal Body Mass Index, Diabetes, and Gestational Weight Gain and Risk for Pediatric Cancer in Offspring: A Systematic Review and Meta-Analysis

Andrew R. Marley, MPH, PhD, Allison Domingues, MS, Taumoha Ghosh, MD, Lucie M. Turcotte, MD, MPH, Logan G. Spector, PhD

1Division of Epidemiology & Clinical Research, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA; 2Division of Hematology/Oncology, Department of Pediatrics, University of Miami, Miami, FL, USA; 3Division of Hematology/Oncology, Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA; and 4Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA

Correspondence to: Andrew R. Marley, MPH, PhD, Department of Pediatrics, University of Minnesota Medical School, 420 Delaware St SE, Minneapolis, MN 55455, USA (e-mail: amarley@umn.edu).

Abstract

Background: Pediatric cancer incidence has steadily increased concurrent with rising adult obesity, but associations between maternal obesity and associated comorbidities and pediatric cancer risk remain understudied. We aimed to quantitatively characterize associations of pediatric cancer risk with maternal prepregnancy body mass index (BMI), gestational weight gain, and maternal diabetes.

Methods: We performed a comprehensive and systematic literature search in Ovid and EMBASE from their inception to March 15, 2021. Eligible studies reported risk estimates and sample sizes and provided sufficient description of outcome and exposure ascertainment. Random effects models were used to estimate pooled effects.

Results: Thirty-four studies were included in the analysis. Prepregnancy BMI was positively associated with leukemia risk in offspring (odds ratio [OR] per 5-unit BMI increase = 1.07, 95% confidence intervals [CI] = 1.04 to 1.11; $I^2 = 0.0\%$). Any maternal diabetes was positively associated with acute lymphoblastic leukemia risk (OR = 1.46, 95% CI = 1.28 to 1.67; $I^2 = 0.0\%$), even after restricting to birthweight-adjusted analyses (OR = 1.74, 95% CI = 1.29 to 2.34; $I^2 = 0.0\%$), and inversely associated with risk of central nervous system tumors (OR = 0.73, 95% CI = 0.55 to 0.97; $I^2 = 0.0\%$). Pregestational diabetes (OR = 1.57, 95% CI = 1.11 to 2.24; $I^2 = 26.8\%$) and gestational diabetes (OR = 1.40, 95% CI = 1.12 to 1.75; $I^2 = 0.0\%$) were also positively associated with acute lymphoblastic leukemia risk. No statistically significant associations were observed for gestational weight gain.

Conclusions: Maternal obesity and diabetes may be etiologically linked to pediatric cancer, particularly leukemia and central nervous system tumors. Our findings support weight management and glycemic control as important components of maternal and offspring health. Further validation is warranted.

Although pediatric cancers remain rare, their global incidence is increasing. In the United States, pediatric cancer incidence is increasing by an average of 0.8% per year and has increased by almost 40% since the mid-1970s, making them the second-leading cause of death among US children. In addition to the immediate challenges of a pediatric cancer diagnosis, including risk of death, pediatric cancer patients are more likely to experience adverse late effects, including premature aging, cognitive deficits, obesity, infertility, and secondary cancers (5-8), highlighting the need to identify risk factors and opportunities for primary prevention.
prevalence of adult obesity has seen a concurrent rise (13,14), with US adult obesity more than tripling from 13% in 1960 to 42% in 2018 (15). Obesity is linked to 13 adulthood cancers and is potentially associated with others (16,17). Given obesity prevalence and its association with adult cancer risk, there is increasing interest in the role of maternal obesity as a risk factor for childhood cancer in offspring. The objective of this meta-analysis is to characterize the association of childhood cancer with maternal obesity and associated comorbidities, including pregestational diabetes (PGD), gestational diabetes (GD), and gestational weight gain (GWG). As maternal obesity and diabetes are also associated with known pediatric cancer risk factors, including congenital abnormalities and birthweight (18-23), it is critical to understand whether maternal obesity and associated comorbidities play a meaningful, independent role in the etiology of pediatric cancer.

Methods

We conducted this meta-analysis according to Preferred Reporting Items for Systematic reviews and Meta-analyses guidelines (24).

Search Strategy and Eligibility Criteria

A comprehensive and systematic literature search was performed in Ovid and EMBASE databases from their inception (1946 for Ovid, 1947 for EMBASE) to March 15, 2021. Search terms used can be found in the Supplementary Methods (available online). For inclusion in the analyses, eligible studies needed to meet the following criteria: published in English; were nested case-control, case-control, cohort, or case-cohort; analyzed childhood cancer risk as outcome of interest and included prepregnancy body mass index (BMI), maternal diabetes (pregestational and/or gestational), or GWG as exposure variables; reported risk estimates (odds ratio [OR], standardized incidence ratio, hazard ratio, or relative risk); reported sample sizes; described how outcome and exposure variables were ascertained. Studies were excluded if they did not meet these criteria; if they were not completed, published, or peer-reviewed studies; or if they provided incompatible exposure data.

Data Extraction and Quality Assessment

Two reviewers (AM and AD) independently performed the data extraction and quality assessment. Extracted data included first author, study year, study design, study period, country of origin, type of cancer(s), sample, patients, controls, age range, ascertainment of BMI and/or diabetes and/or GWG, number of mothers in various exposure categories, ascertainment of cancer diagnosis, method of analysis, effect sizes and 95% confidence intervals (CIs), and adjusted covariates. The Newcastle-Ottawa Scale was used to assess the quality of each included study. Quality was judged on study group selection, group comparability, and ascertainment of the exposure or outcome of interest (25). Scores of 7-9 were considered high quality, 4-6 were considered moderate quality, and 1-3 were considered poor quality.

Statistical Analyses

Summary odds ratios and 95% confidence intervals were estimated to assess effects of prepregnancy BMI, maternal diabetes, and GWG on risk of pediatric cancer in offspring. Because pediatric cancer is rare and incidence was low in included cohort studies, we used odds ratios to estimate effect sizes. Data for a given exposure or outcome category were meta-analyzed if the category contained at least 3 effect sizes and confidence intervals extracted from the literature. If an exposure/outcome category contained less than 3 effect sizes, the data were considered insufficient for meta-analysis. Prepregnancy BMI was assessed according to BMI categories defined by the Centers for Disease Control and Prevention (BMI <18.5: underweight; BMI 18.5-24.9: normal weight; BMI 25-29.9: overweight; BMI ≥30: obese) (26). Because not all studies used these cutoffs, we calculated risk per 5-unit increase in prepregnancy BMI using methodology of Il'yasova et al. (27). Maternal diabetes was evaluated as any diabetes, GD, and PGD. If studies provided separate risk estimates for type 1 and type 2 diabetes, we extracted type 2 data as PGD and excluded type 1 data. We assessed GWG as inadequate, appropriate, and excessive according to weight gain guidelines by the Institute of Medicine (28). Because several studies presented GWG as raw weight gain, however, we also provided risk estimates per 5-kilograms of GWG.

Random effects models were used to estimate summary odds ratios and 95% confidence intervals when heterogeneity was greater than 25%; when heterogeneity was less than 25%, fixed effect models were used. I² was used to assess between-study heterogeneity. Data were grouped together to perform meta-analyses for any cancer and, when data were sufficient, for individual cancers, including acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), any leukemia, neuroblastoma, retinoblastoma, hepatoblastoma, central nervous system (CNS) tumors, Wilms tumor, germ cell tumors, rhabdomyosarcoma, and lymphoma. Where data allowed, subgroup analyses were performed according to study design (case-control and nested case-control vs cohort and case-cohort) and location (North America vs Europe and other). Sensitivity analyses were performed to evaluate result robustness, including restricting to high-quality studies for all statistically significant main analyses. Associations for individual cancer types were considered suggestive if upper- and lower-bound confidence intervals were 1.00 to 1.05 and 0.95 to 1.00, respectively. Funnel plots and Egger tests (P < .05) were used to evaluate publication bias. Stata 16.1 (Stata Corp, College Station, TX) was used for all analyses. Tests were 2-sided, with P values less than .05 indicating statistical significance.

Results

Study Selection and Characteristics

Overall, 10917 citations were retrieved from the literature search, and 9 additional citations were identified from reference lists. After excluding duplicates, non-English articles, review articles, and nonhuman studies, 8835 citations were screened, with 34 studies included in our meta-analysis (Figure 1).

Nine studies provided eligible prepregnancy BMI data (Supplementary Table 1, available online) (29-37). An additional 7 studies with maternal prepregnancy weight data were found but excluded because of vague obesity definitions/lack of ascertainment description (38,39), providing weight rather than BMI (40-42),
or expressing BMI in categories that could not be converted into usable data (43,44). Eligible studies covered 3,404,747 participants and 14,706 childhood cancer patients across 5 countries. Of the studies, 25 provided diabetes data (Supplementary Table 2, available online) (29,32,36,38,39,41,42,45-62) and covered 14,748,772 participants and 44,628 childhood cancer patients from 12 countries, and 11 studies provided GWG data (Supplementary Table 3, available online) (29-34,37,40-42,63). Two additional GWG studies were found but excluded because of weight gain expressed in unusable categories (39,55). Eligible studies covered 2,124,647 participants and 15,915 pediatric cancer patients from 4 countries. Of the 34 included studies, 28 were considered high quality, and 6 were considered moderate quality (Supplementary Tables 4 and 5, available online). A heat map was created to summarize meta-analysis results across all exposures and tumors (Figure 2).

Prepregnancy BMI and Childhood Cancer Risk in Offspring

To assess prepregnancy BMI at an equivalent scale and ensure all eligible data were analyzed, we calculated risk per 5-unit increase in BMI (Figure 3). Data were sufficient to meta-analyze associations for any leukemia, any lymphoma, any CNS tumor, embryonal CNS tumors, and retinoblastoma. Although unable to analyze ALL or AML individually, we identified a statistically significant association for any leukemia, finding a 7% increased leukemia risk in offspring for each 5-unit increase in maternal prepregnancy BMI (OR = 1.07, 95% CI = 1.04 to 1.11; I² = 0.0%, heterogeneity P = .43) with no evidence of publication bias according to Egger test (P = .92). No other statistically significant results were seen, although we found suggestive evidence of an inverse association for CNS tumors (OR = 0.94, 95% CI = 0.86 to 1.03; I² = 28.4%, heterogeneity P = .24), particularly embryonal CNS tumors (OR = 0.89, 95% CI = 0.78 to 1.02; I² = 0.0%, heterogeneity P = .57). There were insufficient data to meta-analyze neuroblastoma, hepatoblastoma, Wilms tumor, germ cell tumors, and rhabdomyosarcoma.

Any Maternal Diabetes and Childhood Cancer Risk in Offspring

We analyzed maternal diabetes as any diabetes, PGD, and GD. We found a statistically significant association between any diabetes and any cancer (OR = 1.20, 95% CI = 1.12 to 1.29; I² = 1.7%, heterogeneity P = .44) (Supplementary Figure 1, available online). For individual cancers, we had sufficient data to meta-analyze associations for any leukemia, ALL, any lymphoma, any CNS tumor, neuroblastoma, retinoblastoma, Wilms tumor, and hepatoblastoma. As seen in Figure 4, we found a positive association for any leukemia (OR = 1.34, 95% CI = 1.19 to 1.51; I² = 0.0%, heterogeneity P = .53, Egger P = .41) and a stronger effect for ALL (OR = 1.46, 95% CI = 1.28 to 1.67; I² = 0.0%, heterogeneity P = .59, Egger P = .68). Sensitivity analyses were performed to determine whether high birthweight could explain associations between...
### Table

| Cancer Type               | Odds Ratio (95% CI)          |
|---------------------------|-------------------------------|
| **Any leukemia**          |                               |
| ALL                       | 1.07 (1.04 to 1.11)           |
| AML                       | 1.34 (1.19 to 1.51)           |
| **Any lymphoma**          |                               |
| Any CNS tumor             | 0.94 (0.86 to 1.03)           |
| Embryonal CNS tumors      | 0.89 (0.78 to 1.02)           |
| Neuroblastoma             |                               |
| Retinoblastoma            |                               |
| Wilms tumor               | 1.51 (0.99 to 2.30)           |
| Hepatoblastoma            | 1.25 (0.95 to 1.64)           |
| Rhabdomyosarcoma          |                               |
| Germ cell tumors          |                               |

### Figure 2

Heat map of the associations between prepregnancy BMI, gestational weight gain, maternal diabetes, and risk of pediatric cancers. Cells depicting statistically significant or suggestive associations display meta-analyzed odds ratios (95% confidence intervals). † Considered suggestive if upper- and lower-bound confidence intervals were 1.00 to 1.05 and 0.95 to 1.00, respectively. For inadequate gestational weight gain (Institute of Medicine defined guidelines) only. ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; BMI = body mass index; CNS = central nervous system.

### Figure 3

**A**

Forest plots: meta-analysis of the association between a 5-unit increase in prepregnancy BMI and risk of (A) any leukemia, (B) central nervous system tumors, and (C) embryonal central nervous system tumors. The error bars represent the 95% confidence intervals (CIs). Fixed effects models (inverse variance method) were used for panels A and C, and random effects models (DerSimonian and Laird method) were used for panel B. Tests were 2-sided. DL = DerSimonian-Laird; IV = inverse variance.
any diabetes and any leukemia or ALL and demonstrated that associations persisted even after restricting to birthweight-adjusted analyses (41,47,48,57,61) (any diabetes OR = 1.56, 95% CI = 1.28 to 1.90; ALL OR = 1.74, 95% CI = 1.29 to 2.34) (Supplementary Figure 2, available online). Additionally, we found any maternal diabetes was inversely associated with risk of CNS tumors (OR = 0.73, 95% CI = 0.55 to 0.97; I² = 0.0%, heterogeneity P = .44) with no evidence of publication bias (Egger P = .19). Data were not sufficient to analyze PGD and CD separately for this association. There were no other statistically significant associations among individual cancers, although lymphoma (OR = 1.51, 95% CI = 0.99 to 2.30; I² = 0.0%, heterogeneity P = .93) and Wilms tumor (OR = 1.25, 95% CI = 0.95 to 1.64; I² = 0.0%, heterogeneity P = .62) provided suggestive evidence of an association (Figure 4). Data for AML, germ cell tumors, and rhabdomyosarcoma were insufficient for meta-analysis.

Figure 4. Forest plots: meta-analysis of the association between any diabetes and risk of (A) any leukemia, (B) acute lymphoblastic leukemia, (C) central nervous system tumors, (D) lymphoma, and (E) Wilms tumor. The error bars represent the 95% confidence intervals (CIs). Fixed effects models (inverse variance method) were used for statistical analyses. Tests were 2-sided. ALL – acute lymphoblastic leukemia; AML – acute myeloid leukemia; IV – inverse variance.
PGD and GD and Childhood Cancer Risk in Offspring

For PGD and GD, we found statistically significant positive associations for any cancer (PGD OR = 1.19, 95% CI = 1.02 to 1.37; $I^2 = 28.8\%$, heterogeneity $P = .11$; GD OR = 1.20, 95% CI = 1.09 to 1.33; $I^2 = 0.0\%$, heterogeneity $P = .65$) (Supplementary Figure 3, available online). We also found positive associations between PGD and GD and risk for ALL and any leukemia. PGD (Figure 5) was associated with a 41% increased risk of any leukemia (OR = 1.41, 95% CI = 1.05 to 1.89; $I^2 = 27.4\%$, heterogeneity $P = .24$, Egger $P = .20$) and a 57% increased risk for ALL (OR = 1.57, 95% CI = 1.11 to 2.24; $I^2 = 26.8\%$, heterogeneity $P = .25$, Egger $P = .31$). No statistically significant associations were found for lymphoma or CNS tumors, and data were insufficient to meta-analyze associations for AML, neuroblastoma, retinoblastoma, Wilms tumor, hepatoblastoma, rhabdomyosarcoma, and germ cell tumors. GD (Figure 6) was associated with a 32% increased risk for any leukemia (OR = 1.32, 95% CI = 1.08 to 1.61; $I^2 = 0.0\%$, heterogeneity $P = .60$, Egger $P = .56$) and a 40% increased risk of ALL (OR = 1.40, 95% CI = 1.12 to 1.75; $I^2 = 0.0\%$, heterogeneity $P = .81$, Egger $P = .16$). No statistically significant associations were found for AML or CNS tumors, and data for lymphoma, neuroblastoma, retinoblastoma, Wilms tumor, hepatoblastoma, rhabdomyosarcoma, and germ cell tumors were insufficient to meta-analyze.

GWG and Childhood Cancer Risk in Offspring

Data were sufficient to meta-analyze GWG data for any leukemia, any CNS tumor, embryonal CNS tumors, and retinoblastoma. Results (any cancer and individual tumors) lacked any statistically significant results; however, we found suggestive evidence of a positive association between inadequate GWG (Institute of Medicine guidelines) and risk of any CNS tumor (OR = 1.29, 95% CI = 0.99 to 1.68; $I^2 = 30.8\%$, heterogeneity $P = .23$) (Figure 7). Data
for ALL, AML, lymphoma, neuroblastoma, Wilms tumor, hepatoblastoma, rhabdomyosarcoma, and germ cell tumors were insufficient for meta-analysis. Funnel plots for results presented in Figures 2-7 analysis are displayed in Figure 8.

Subgroup and Sensitivity Analyses
As data allowed, subgroup analyses were performed according to study geographic region and study design. Subgroup analyses were primarily performed among any cancer, ALL, and any leukemia and among pregestational, gestational, and any diabetes. With some exceptions, effect sizes were larger among studies conducted in other regions vs in North America and among cohort and case-cohort studies vs case-control and nested case-control studies (Supplementary Table 6, available online). Where data allowed, sensitivity analyses restricting to high-quality studies were performed for all statistically significant main results. No appreciable changes were observed.

Discussion
We summarized current evidence evaluating associations between maternal obesity, maternal diabetes, and GWG with risk of pediatric cancers in offspring. We found greater prepregnancy BMI was associated with an increased risk of pediatric leukemia; maternal diabetes was associated with a decreased risk of CNS tumors but increased risk of leukemia, particularly ALL; and inadequate GWG may increase risk for pediatric CNS tumors. To our knowledge, this is the first meta-analysis of prepregnancy BMI and GWG as pediatric cancer risk factors. One prior meta-analysis for maternal diabetes and childhood cancer risk has been recently published (64); however, our meta-analysis includes more studies and greater detail on risks associated with individual tumor types and differing forms of maternal diabetes.

We found a statistically significant 7% increased risk of childhood leukemia for every 5-unit increase in prepregnancy BMI. Obesity has been repeatedly linked to leukemia risk in adult populations (65-67), but recent research has identified links between childhood obesity and childhood leukemia (68-71). Our own research has demonstrated a statistically significant association between childhood obesity and ALL risk among 4726 pediatric leukemia cases (71), suggesting early obesity exposure may propagate pediatric leukemia risk. Obesity may specifically promote leukemogenesis via several mechanisms, including altered adipokine secretion (68), decreased circulating adiponectin (72), and increased leptin bioavailability (73,74). Additionally, as obesity heritability is estimated to be 0.85-0.9 (75,76), obese mothers are more likely to have obese children, thus increasing leukemogenesis risk; however, with our data, there was no way to determine leukemia risk attributable to obesity genomics. These mechanisms may not just apply to obese persons individually, but may confer obesity-associated risk to infants during gestation. Similar mechanisms may be present for other pediatric tumors, however, with limited data available, associations were not detected.

We identified similar, approximately 20% increased risks for any cancer associated with any maternal diabetes and PGD. These results are consistent with a recently published meta-analysis (64), although our summary effect sizes are smaller because of inclusion of several more studies. Our finding for GD was not consistent with the previous meta-
Figure 6. Forest plots: meta-analysis of the association between gestational diabetes and risk of (A) any leukemia and (B) acute lymphoblastic leukemia. The error bars represent the 95% confidence intervals (CIs). Fixed effects models (inverse variance method) were used for statistical analyses. Tests were 2-sided. ALL = acute lymphoblastic leukemia; AML = acute myeloid leukemia; IV = inverse variance.

Figure 7. Forest plot: meta-analysis of the association between inadequate gestational weight gain and risk of central nervous system tumors. The error bars represent the 95% confidence intervals (CIs). Random effects models (DerSimonian and Laird method) were used for statistical analyses. Tests were 2-sided. DL = DerSimonian-Laird.

NOTE: Weights are from random-effects model.
analysis, which found GD to be associated with a non-statistically significant 10% increased cancer risk (OR = 1.10, 95% CI = 0.94 to 1.28) (64). This inconsistency is likely due to the more robust nature of our analysis (15 vs 6 studies). We also found that any diabetes, PGD, and GD were specifically associated with risk of any leukemia and ALL, consistent with the previous meta-analysis (64). Although PGD and GD are associated with differing effect sizes in other perinatal and/or pediatric conditions (77), our findings of similar but slightly higher effect sizes for PGD vs GD indicate both conditions influence pediatric cancer risk via similar mechanisms, with earlier fetal exposure to PGD resulting in a slightly higher risk of pediatric cancer. These findings could also reflect the earlier, quicker onset of other perinatal conditions (ie, congenital

Figure 8. Funnel plots for meta-analysis results of the associations between prepregnancy BMI, maternal diabetes, and gestational weight gain and risk of pediatric cancers. A) Funnel plot for the association between prepregnancy BMI and risk of any leukemia; (B) funnel plot for the association between prepregnancy BMI and risk of central nervous system tumors; (C) funnel plot for the association between prepregnancy BMI and risk of embryonal central nervous system tumors; (D) funnel plot for the association between any diabetes and risk of any leukemia; (E) funnel plot for the association between any diabetes and risk of acute lymphoblastic leukemia; (F) funnel plot for the association between any diabetes and risk of lymphoma; (G) funnel plot for the association between any diabetes and Wilms tumor risk; (H) funnel plot for the association between gestational diabetes and risk of any leukemia; (I) funnel plot for the association between gestational diabetes and risk of acute lymphoblastic leukemia; (J) funnel plot for the association between gestational diabetes and risk of lymphoma; (K) funnel plot for the association between gestational diabetes and risk of Wilms tumor; (L) funnel plot for the association between gestational diabetes and risk of embryonal central nervous system tumors. BMI = body mass index; logor = natural log of the odds ratio; s.e. = standard error.
anomalies) vs the later, longer onset of GD and of leukemogenesis. Mechanistically, these findings may be due to decreased levels of adiponectin and higher levels of insulin-like growth factors (IGF)-1 and leptin associated with gestational and type 2 diabetes (78-80), as well as increased fetal oxidative stress, altered fetal metabolism (80,81), and epigenetic modifications (82) associated with maternal hyperglycemia. Maternal diabetes may also promote leukemogenesis via its impact on birthweight. Maternal hyperglycemia is associated with large for gestational age offspring (83), a well-established leukemia risk factor (84,85). However, when restricting birthweight-adjusted analyses, we found the
association between any diabetes and any leukemia persisted, suggesting other biological mechanisms may be relevant. An association between GWG and risk of pediatric cancer was not identified. Although GWG was hypothesized to impact offspring cancer risk via similar mechanisms as prepregnancy BMI, our lack of statistically significant findings indicates that temporary GWG, even when excessive, does not confer the same risks as longer-term overweight or obesity. We identified unexpected and interesting results for CNS tumors. We found a statistically significant inverse association between any maternal diabetes and CNS tumor risk (OR = 0.73, 95% CI = 0.55 to 0.97). To assess whether this result may be a function of data quality, we performed a sensitivity analysis and found no appreciable difference when restricting to studies considered high quality (OR = 0.73, 95% CI = 0.54 to 0.98). Additionally, we found suggestive evidence of inverse associations for CNS tumors, including a decreased CNS tumor risk per 5-unit BMI increase and an increased risk of CNS tumors associated with inadequate GWG. These findings have not been widely researched, thus we can only speculate as to underlying causes. One hypothesis involves adipokines interacting with the blood-brain barrier and exerting CNS effects. Increasing adiposity results in increased secretion of adipokines. Transforming growth factor–β1, an adipokine that can act at the blood-brain barrier and has potent anti-inflammatory properties, may protect against metabolic disturbances (86,87) and therefore protect against CNS tumorigenesis. Another hypothesis speculates that, because diabetes is associated with decreased IGF-1, and IGF-1 has been demonstrated to stimulate glioma cell division (88), diabetes may protect against CNS tumorigenesis via the IGF pathway. Again, these speculative hypotheses need to be further studied and understood.

Our meta-analysis is subject to several limitations. As with all analyses of observational studies, we cannot rule out residual confounding, and as many case-control studies were included in the analyses, results are subject to recall bias; also, included studies adjusted for different covariates. Furthermore, only a few studies adjusted for established risk factors such as congenital anomalies or radiographic exposure. Also notable, none of the maternal diabetes studies adjusted for prepregnancy BMI, and none of the included studies adjusted for child’s weight or BMI at time of diagnosis, allowing for possible confounding. Additionally, lack of available data limited our ability to analyze individual tumors, and therefore some outcomes were analyzed according to cancer groupings (eg, all leukemia, CNS tumors, lymphoma). As various cancers within a grouping can have distinct etiologies, grouped results should be interpreted with caution. Analyses were particularly limited for neuroblastoma, hepatoblastoma, Wilms tumor, and AML, and no analyses were possible for germ cell tumors and rhabdomyosarcoma. Finally, we were limited by differences in GWG categorization, disallowing us from combining these data as we did for prepregnancy BMI.

These findings advance knowledge of pediatric cancer risk factors and have direct implications for clinical practice. Our findings highlight the importance of maintaining health checkups before and throughout pregnancy and emphasize glycemic control as an important part of prenatal and perinatal health. These findings also highlight the importance of weight management for both maternal and offspring health. Lastly, for mothers struggling with excessive weight gain, our GWG findings may offer reassurance that such gain is not associated with increased risk of childhood malignancies.

In conclusion, the current meta-analysis provides evidence that maternal obesity and diabetes may play a role in the development of pediatric malignancies, specifically for leukemias and CNS tumors. Further investigation is needed to support these variables as potential factors in the etiology of pediatric cancers and confirm our novel findings.

**Funding**

This work was supported by the National Cancer Institute [T32 CA099936 to LS].

**Notes**

**Role of the funder:** The funder had no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; or the decision to submit the manuscript for publication.

**Author contributions:** Conceptualization (TG, LT, LS); data curation (AM, AD); formal analysis (AM), funding acquisition (LS); investigation (AM, AD, TG); methodology (AM, AD, TG); project administration (LS, LT); resources & software (AM, AD); writing—original draft (AM, TG); writing—review & editing (all authors).

**Data Availability**

Data analyzed for this study are contained within the manuscript and/or its supplementary materials.

**References**

1. Hubbard AK, Spector LG, Fortuna G, Marcotte EL, Poynter JN. Trends in international incidence of pediatric cancers in children under 5 years of age: 1988-2012. JNCI Cancer Spectr. 2019;3(1):pkz007.

2. Centers for Disease Control and Prevention. Annual Report to the Nation: Cancer Death Rates Continue to Decline. https://www.cdc.gov/media/releases/2020/p0312-annual-report.html. Accessed March 15, 2022.

3. National Cancer Institute. SEER Cancer Statistics Review (CSR) 1975-2017. National Cancer Institute: 2020. https://seer.cancer.gov/archive/csr/1975_2017/. Accessed June 08, 2021.

4. Centers for Disease Control and Prevention. Leading Causes of Death and Injury. https://www.cdc.gov/injury/wisqars/LeadingCauses.html. Accessed June 08, 2021.

5. Henderson TO, Ness KK, Cohen HJ. Accelerated aging among cancer survivors: from pediatrics to geriatrics. Am Soc Clin Oncol Educ Book. 2014;34(34):e423–e430.

6. Landier W, Armenian S, Bhatia S. Late effects of childhood cancer and its treatment. Pediatr Clin North Am. 2015;62(1):275–300.

7. Kopp LM, Gupta F, Pelayo-Katsanis L, Wittman B, Katsanis E. Late effects in adult survivors of pediatric cancer: a guide for the primary care physician. Am J Med. 2012;125(7):636–641.

8. Ghol DK, Helenowski I, Hjinya N. Secondary malignancies in pediatric cancer survivors: perspectives and review of the literature. Int J Cancer. 2014;135(8):1764–1773.

9. Marcotte EL, Thomopoulos TP, Infante-Rivard C, et al. Caesarean delivery and risk of childhood leukemia: a pooled analysis from the Childhood Leukemia International Consortium (CLIC). Lancet Haematol. 2016;3(4):e176–e185.

10. Petridou ET, Georgakis MK, Erdmann F, et al. Advanced parental age as risk factor for childhood acute lymphoblastic leukemia: results from studies of the Childhood Leukemia International Consortium. Eur J Epidemiol. 2018;33(10):965–976.

11. O’Neill KA, Murphy MF, Bunch KJ, et al. Infant birthweight and risk of childhood cancer: international population-based case control studies of 40 000 cases. Int J Epidemiol. 2015;44(1):153–168.

12. Spector LG, Pankratz N, Marcotte EL. Genetic and nongenetic risk factors for childhood cancer. Pediatr Clin North Am. 2015;62(1):11–25.

13. Skinner AC, Skelton JA. Prevalence and trends in obesity and severe obesity among children in the United States, 1999–2012. JAMA Pediatr. 2014;168(8):561–566.
69. Orgel E, Tucci J, Alhushki W, et al. Obesity is associated with residual leukemia following induction therapy for childhood B-precursor acute lymphoblastic leukemia. Blood. 2014;124(26):3932–3938.

70. Mittelman SD, Kim J, Raca G, Li G, Oberley MJ, Orgel E. Increased prevalence of CRLF2 rearrangements in obesity-associated acute lymphoblastic leukemia. Blood. 2021;138(2):199–202.

71. Ghosh T, Richardson M, Gordon PM, Ryder JR, Spector LG, Turcotte LM. Body mass index associated with childhood and adolescent high-risk B-cell acute lymphoblastic leukemia risk: a Children’s Oncology Group report. Cancer Med. 2020;9(18):6825–6835.

72. El-Baz HA, Mosa TE, Elabd EM, et al. Serum adiponectin and resistin levels in de novo and relapsed acute lymphoblastic leukemia children patients. Iran J Public Health. 2013;42(5):504.

73. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer. 2004;4(8):579–591.

74. Hino M, Nakao T, Yamane T, Ohta K, Takubo T, Tatsumi N. Leptin receptor and leukemia. Leuk Lymphoma. 2000;36(5-6):457–461.

75. Elks CE, Den Hoed M, Zhao JH, et al. Variability in the heritability of body mass index: a systematic review and meta-regression. Front Endocrinol (Lausanne). 2012;3:29.

76. Feng R. How much do we know about the heritability of BMI? Am J Clin Nutr. 2016;104(2):243–244.

77. Sharpe PB, Chan A, Haan EA, Hiller JE. Maternal diabetes and congenital anomalies in South Australia 1986-2000: a population-based cohort study. Birth Defects Res A Clin Mol Teratol. 2005;73(9):605–611.

78. Lauszus FF, Klebe JG, Flyvbjerg A. Macrosomia associated with maternal serum insulin-like growth factor-I and-II in diabetic pregnancy. Obstet Gynecol. 2001;97(5):734–741.

79. Jansson N, Nilsson A, Gellerstedt M, et al. Maternal hormones linking maternal body mass index and dietary intake to birth weight. Am J Clin Nutr. 2008;87(6):1743–1749.

80. Dimasuay KG, Boesf P, Powell TL, Jansson T. Placental responses to changes in the maternal environment determine fetal growth. Front Physiol. 2016;7:12.

81. Sarikabadayi YU, Aydemir O, Aydemir C, et al. Umbilical cord oxidative stress in infants of diabetic mothers and its relation to maternal hyperglycemia. J Pediatr Endocrinol Metab. 2011;24(9-10):671–674.

82. Ma RG, Tutino GE, Lillycrop KA, Hanson MA, Tam WH. Maternal diabetes, gestational diabetes and the role of epigenetics in their long term effects on offspring. Prog Biophys Mol Biol. 2015;118(1-2):55–68.

83. Kerényi Z, Tamás G, Kivimäki M, et al. Maternal glycemia and risk of large-for-gestational-age babies in a population-based screening. Diabetes Care. 2009;32(12):2200–2205.

84. Hjalgrim LL, Westergaard T, Rostgaard K, et al. Birth weight as a risk factor for childhood leukemia: a meta-analysis of 18 epidemiologic studies. Am J Epidemiol. 2003;158(8):724–735.

85. Caughey RW, Michels KB. Birth weight and childhood leukemia: a meta-analysis and review of the current evidence. Int J Cancer. 2009;124(11):2658–2670.

86. Qian L, Wei S-J, Zhang D, et al. Potent anti-inflammatory and neuroprotective effects of TGF-β1 are mediated through the inhibition of ERK and p47phox-Ser345 phosphorylation and translocation in microglia. J Immunol. 2008;181(1):660–668.

87. Pan W, Kastin AJ. Adipokines and the blood-brain barrier. Peptides. 2007;28(6):1137–1330.

88. Trojan J, Cloix J-F, Ardourel M-Y, Chatel M, Anthony D. Insulin-like growth factor type I biology and targeting in malignant gliomas. Neuroscience. 2007;145(3):795–811.